Adjuvant Therapy in Renal Cell Carcinoma: Current Status and Future Directions

被引:1
|
作者
Kazarian, Austin G. [1 ]
Chawla, Neal S. [2 ]
Muddasani, Ramya [2 ]
Pal, Sumanta K. [2 ]
机构
[1] Univ Iowa, Carver Coll Med, Iowa City, IA USA
[2] City Hope Comprehens Canc Ctr, Dept Med Oncol & Expt Therapeut, 1500 East Duarte Rd, Duarte, CA 91010 USA
关键词
Renal cell carcinoma; adjuvant chemotherapy; cytokines; molecular targeted therapy; precision medicine; BLIND PHASE-III; HIGH-RISK; RADICAL NEPHRECTOMY; INTERFERON-ALPHA; TRIAL; INTERLEUKIN-2; STAGE; RECURRENCE; SURVIVAL; IMMUNOTHERAPY;
D O I
10.3233/KCA-200105
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In recent years, incredible progress has been made in the treatment of metastatic renal cell carcinoma, with a paradigm shift from the use of cytokines to tyrosine kinase inhibitors, and more recently, immune checkpoint inhibitors (ICIs). Despite advances in the metastatic setting, effective therapies in the adjuvant setting are a largely unmet need. Currently, sunitinib (Sutent, Pfizer) is the only therapy for the adjuvant treatment of RCC included in the National Comprehensive Cancer Network guidelines, which was approved by the FDA based on the improvement in disease-free survival (DFS) seen in the S-TRAC trial. However, improvement in DFS has not translated into an overall survival (OS) benefit for patients at high-risk of relapse post-nephrectomy, illustrating the need for more effective therapies. This manuscript will highlight attributes of both historical and current drug trials and their implications on the landscape of adjuvant therapy. Additionally, we will outline strategies for selecting patients in whom treatment would be most beneficial, as optimal patient selection is a crucial step towards improving outcomes in the adjuvant setting. This is especially critical, given the financial cost and pharmacological toxicity of therapeutic agents. Furthermore, we will review the design of clinical trials including the value of utilizing OS as an endpoint over DFS. Finally, we will discuss how the incorporation of genomic data into predictive models, the use of more sensitive imaging modalities for more accurate staging, and more extensive surgical intervention involving lymph node dissection, may impact outcomes.
引用
收藏
页码:9 / 20
页数:12
相关论文
共 50 条
  • [1] Renal cell carcinoma: current status and future directions
    Martel, CL
    Lara, PN
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2003, 45 (02) : 177 - 190
  • [2] Adjuvant therapy for renal cell carcinoma: A systematic review of current landscape and future directions
    Bolek, Hatice
    Urun, Yuksel
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2023, 192
  • [3] Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma
    Considine, Bryden
    Hurwitz, Michael E.
    CURRENT ONCOLOGY REPORTS, 2019, 21 (04)
  • [4] Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma
    Bryden Considine
    Michael E. Hurwitz
    Current Oncology Reports, 2019, 21
  • [5] Treatment of renal cell carcinoma: Current status and future directions
    Barata, Pedro C.
    Rini, Brian I.
    CA-A CANCER JOURNAL FOR CLINICIANS, 2017, 67 (06) : 507 - 524
  • [6] Adjuvant treatment for renal cell carcinoma: current status and future
    Leung, David K. W.
    Siu, Brian W. H.
    Teoh, Jeremy Y. C.
    CURRENT OPINION IN UROLOGY, 2025, 35 (01) : 41 - 45
  • [7] Current status and future directions of molecular markers in renal cell carcinoma
    Rini, Brian I.
    CURRENT OPINION IN UROLOGY, 2006, 16 (05) : 332 - 336
  • [8] Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives
    Larroquette, Mathieu
    Peyraud, Florent
    Domblides, Charlotte
    Lefort, Felix
    Bernhard, Jean-Christophe
    Ravaud, Alain
    Gross-Goupil, Marine
    CANCER TREATMENT REVIEWS, 2021, 97
  • [9] Adjuvant therapy for pancreatic cancer: Current status, future directions
    Regine, William F.
    Abrams, Ross A.
    SEMINARS IN ONCOLOGY, 2006, 33 (06) : S10 - S13
  • [10] Adjuvant therapy of colon cancer: Current status and future directions
    Chung, Ki Young
    Saltz, Leonard B.
    CANCER JOURNAL, 2007, 13 (03): : 192 - 197